Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-03-31
Disclosure Type: Results of Annual General Meeting of Shareholders
💡 3-Second Summary
Alteogen held its Annual General Meeting on March 31, approving the 17th fiscal year financial statements with consolidated revenue of KRW 102.85B. All presented items, including the re-election of CEO Park Soon-jae and the granting of stock options, were approved as originally proposed with no dividend payouts.
📊 1. [Summary of Core Disclosure Content and Key Figures]
- AGM Date: March 31, 2025
- FY17 Key Financial Figures & Audit Opinions (In Millions of KRW / Auditor Opinion: Unqualified):
- Consolidated: Total Assets 409,012 / Total Liabilities 134,921 / Total Equity 274,091 / Revenue 102,855 / Operating Income 25,404 / Net Income 60,690 / Earnings Per Share (EPS) KRW 1,172
- Separate: Total Assets 331,648 / Total Liabilities 30,521 / Total Equity 301,127 / Revenue 92,969 / Operating Income 30,630 / Net Income 71,233 / Earnings Per Share (EPS) KRW 1,341
- Dividend Resolutions: No cash, property, or stock dividends resolved (-)
- Executive Appointments and Corporate Governance Status:
- Re-election of Inside Director Park Soon-jae (3-year term, current CEO of Alteogen)
- New appointment of Inside Director Choi Sang-rak (3-year term, current Vice President of Alteogen)
- New appointment of Standing Auditor Lee Jung-min (3-year term, current Auditor of Altos Biologics)
- Post-AGM Governance: 6 Total Directors (including 2 Outside Directors, Outside Director Ratio: 33.3%), 1 Standing Auditor
- Resolution Results of Other Agenda Items: Agenda Item 1 (Approval of Financial Statements), Item 2 (Appointment of Directors), Item 3 (Appointment of Auditor), Item 4 (Approval of Ceiling on Director Compensation), Item 5 (Approval of Ceiling on Auditor Compensation), and Item 6 (Approval of Granting Stock Options) were all approved as originally proposed.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This operational filing serves as an administrative announcement publishing the finalized financial parameters and governance appointments following the conclusion of Alteogen’s 17th Annual General Meeting. The voting outcome confirms that the agenda items tabled by the board were approved as originally proposed, functioning as a regular corporate notification rather than an event that introduces near-term market demand changes.
Investors should focus on the validated financial metrics, noting that consolidated revenue reached KRW 102,855M while consolidated operating income stood at KRW 25,404M under an unqualified audit status. Standalone net income (KRW 71,233M) outpaced consolidated net income (KRW 60,690M), aligning with internal reporting parameters. Furthermore, the successful re-election of founder and CEO Park Soon-jae may exert a positive potential impact by supporting management continuity. The disclosure does not explain the specific causes of financial performance fluctuations. Investors are advised to analyze this report as an official confirmation of the corporate voting result without making definitive assumptions regarding the company’s broader business fundamentals.
📝 Editor’s Comment (by K-STOCK Editor)
Alteogen’s 17th Annual General Meeting has concluded with the standard approval of all proposed resolutions. This filing is a factual summary recording the technical finalization of financial records and executive management structures. Earnings per share settled at KRW 1,341 on a separate basis and KRW 1,172 on a consolidated basis, with zero capital distribution directed toward dividends. As CEO Park Soon-jae secures a renewed 3-year mandate, supporting management continuity, market participants should objectively monitor the updated board composition and documented executive backgrounds based purely on official metrics.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!